Locus Biosciences

Locus Biosciences, founded in 2015, is a biotechnology company focused on developing CRISPR-engineered precision antibacterial products. Their core mission is to combat the growing antimicrobial resistance (AMR) pandemic and treat diseases of the microbiome. The company offers innovative precision medicines designed to target specific bacterial infections, leveraging CRISPR technology to enhance the efficacy and specificity of their treatments. Locus Biosciences primarily targets markets affected by high-prevalence bacterial infections, such as urinary tract infections (UTIs).

Notable figures associated with Locus Biosciences include its founders and key investors who have supported its mission. The company has achieved significant milestones, including securing substantial funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the first phase trial of its CRISPR-engineered bacteriophage therapy. Locus Biosciences has made a considerable impact in the field of biotechnology by pioneering advanced solutions to address AMR and microbiome-related diseases, positioning itself as a leader in precision antibacterial therapies.